“editas-medicine” Archives

in
Entry Author Date Location
Scribe Therapeutics Sets Out to Write CRISPR Gene Editing’s Next Chapter 10/06/20 San Francisco
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact 08/07/20 Boston
Bio Roundup: Cerevel’s Shell, Thrive’s Rise, Drug Price Drama & More 07/31/20 National
Verve Therapeutics Adds $63M to Edit Heart Attack Risk Out of Genes 06/11/20 Boston
Generation Bio Leads a Trio of Biotech Companies Aiming for the Nasdaq 05/22/20 National
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More 03/06/20 National
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019 02/12/20 National
Biotech Roundup: Novartis on Hold, AMAG Vote, Neuro News & More 11/01/19 National
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More 10/18/19 National
Beam Therapeutics Preps IPO and Sheds Light on Its Gene-Editing Drugs 09/27/19 Boston
Bayer Buys Out BlueRock, Betting at Least $240M More on Cell Therapy Work 08/08/19 Boston
Xconomy Awards: Gilman & Bosley to Emcee Life Science Gala in Boston 06/20/19 Boston
Laurie Glimcher To Headline Xconomy Keynote Series in Boston in September 05/16/19 Boston
Verve Has Top Cardio-Geneticist, $58.5M to Aim CRISPR at Heart Attacks 05/07/19 Boston
Precision Bio’s IPO Raises $126M for Pipeline of Gene-Edited Drugs 03/27/19 Raleigh Durham
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More 01/25/19 National
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial 01/22/19 Boston
15 For ’19: Key Clinical Data to Watch For Next Year (Part 2) 12/18/18 National
Sarepta Touts New Data and a “Signal” With Duchenne Gene Therapy 10/03/18 Boston
Morphic Nets Another $80M For Integrin Drugs & First Human Tests 09/25/18 Boston
Bio Roundup: Drug Prices, CRISPR Caveats, Rubius IPO Pop & More 07/20/18 National
New Study Shows CRISPR Can Delete Big Chunks of DNA 07/16/18 National
Bio Roundup: Not-BIO Party Foul, CRISPR Drama, Sickle Cell Updates 06/15/18 National
Benchling Scores $14.5M to Grow Online Lab Notebook for Bio-Researchers 06/14/18 San Francisco
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells 06/11/18 National
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M 05/14/18 Boston
New CRISPR Startup from Feng Zhang Revealed 04/27/18 Boston
Home Tests in Mind, Doudna Startup Races Rivals in CRISPR Diagnostics 04/26/18 San Francisco
Continuing Cell Therapy Push, Gilead Aligns with Sangamo for CAR-T Boost 02/22/18 San Francisco
CRISPR Could Soon Charge into Hearing Loss Drug Race, New Study Suggests 12/20/17 National
Page 1 of 5 next page »